Literature DB >> 28396326

Regulator or regulatory shield? The case for reforming Canada's Patented Medicine Prices Review Board.

Rujun Zhang1, Danielle Martin2, C David Naylor2.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28396326      PMCID: PMC5386843          DOI: 10.1503/cmaj.161355

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  2 in total

1.  Drug prices: How do we get to a better place?

Authors:  Joel Lexchin
Journal:  CMAJ       Date:  2017-06-12       Impact factor: 8.262

2.  Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?

Authors:  Nigel Sb Rawson; John Adams
Journal:  Clinicoecon Outcomes Res       Date:  2017-11-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.